论文部分内容阅读
目的:推导并定量分析哌拉西林/他唑巴坦抗铜绿假单胞菌感染疗效的PK/PD预测参数T>MIC%,并以此评价和优化用药方案。方法:以一室药动学模型为基础,依据哌拉西林/他唑巴坦对铜绿假单胞菌的PK/PD参数推导T>MIC%的表达式,采用单剂量和多剂量重复多次静滴给药的药动学公式计算常规方案(哌拉西林/他唑巴坦4.5 g+0.9%氯化钠注射液100 ml ivd q8h)的T>MIC%并与PK/PD理论认为的该值优化范围比较,分析该方案T>MIC%的达标情况;同时将原方案的间隔时间由8 h延长至16 h,同法考察T>MIC%的达标情况。结果:针对铜绿假单胞菌,哌拉西林/他唑巴坦常规方案的T>MIC%,依据单剂量和多剂量重复多次静滴给药药动学公式计算结果分别为99.96%和99.99%,远远超过优化达标范围;间隔时间延长法的T>MIC%为54.7%,达标。结论:药动学公式定量分析哌拉西林/他唑巴坦抗铜绿假单胞菌感染的PK/PD预测参数,理论上可评价和优化该类感染使用该种药物的临床用药方案,对此具有一定的理论指导意义。
OBJECTIVE: To deduce and quantify the PK / PD prediction parameter T> MIC% of piperacillin / tazobactam against P. aeruginosa infection and to evaluate and optimize the drug regimen. Methods: Based on the one-compartment pharmacokinetic model, the expression of T> MIC% was deduced based on the PK / PD parameters of piperacillin / tazobactam to Pseudomonas aeruginosa. The single-dose and multi-dose repeated The pharmacokinetic formula for intravenous administration calculates T> MIC% for the conventional regimen (piperacillin / tazobactam 4.5 g + 0.9% sodium chloride injection 100 ml ivd q8h) and compares this with the PK / PD theory Value of the optimization range, analysis of the program T> MIC% of the standard situation; at the same time the original program interval from 8 h to 16 h, the same method to examine T> MIC% of compliance. Results: T> MIC% of conventional solutions of Pseudomonas aeruginosa and piperacillin / tazobactam were 99.96% and 99.99%, respectively, according to the pharmacokinetic formulas of single and multiple doses repeated intravenous administration %, Far exceeding the scope of the optimal compliance; interval time extension method T> MIC% of 54.7%, up to standard. CONCLUSIONS: The pharmacokinetic formula for the quantitative analysis of PK / PD predictive parameters against piperacillin / tazobactam against P. aeruginosa infections can theoretically evaluate and optimize the clinical regimen for this type of infection using this drug, Has a certain theoretical significance.